Abstract
Psychiatric adverse events have been associated with rapid titration and high doses of most antiepileptic drugs (AEDs). However, several AEDs can cause such events at any dose. These agents include barbiturates, topiramate, levetiracetam and zonisamide. A search of the literature reveals that psychiatric adverse events associated with these AEDs seem not to occur at random. Rather, they are most likely to be reported by patients who have an inherent vulnerability to psychiatric disorders; that is, those with a personal or family history of psychiatric illness. In a recent study by Mula et al., patients who underwent rapid titration of topiramate had a fivefold increase in risk of depressive episodes. In patients with a history of depression, however, the risk increase was 23.3-fold. Thus, clinicians must ascertain a patient's personal and family psychiatric history before choosing an AED and planning the dose titration regimen.
This is a preview of subscription content, log in via an institution to check access.
References
Brent DA et al. (1987) Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 80: 909–917
Levinson DF and Devinsky O (1999) Psychiatric adverse events during vigabatrin therapy. Neurology 53: 1503–1511
Leppik IE (1995) Tiagabine: the safety landscape. Epilepsia 36 (Suppl 6): S10–S13
Mula M et al. (2003) Psychiatric adverse events during levetiracetam therapy. Neurology 61: 704–706
Mula M et al. (2003) Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 48: 2322–2326
Trimble RM et al. (2000) Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 9: 249–254
Kanner AM et al. (2003) A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 4: 548–552
Mula M et al. (2008) The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia [10.1111/j.1528-1167.2008.01799.x]
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Dr Kanner has acted as a consultant, been a member of speakers' bureaus or received honoraria from GlaxoSmithKline, Ortho-McNeill, Pfizer, and UCB. He has received grant or research support from GlaxoSmithKline and Novartis.
Rights and permissions
About this article
Cite this article
Kanner, A. Can antiepileptic drugs unmask a susceptibility to psychiatric disorders?. Nat Rev Neurol 5, 132–133 (2009). https://doi.org/10.1038/ncpneuro1051
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro1051
- Springer Nature Limited